NAUT Insider Trading

Insider Ownership Percentage: 40.50%
Insider Buying (Last 12 Months): $52,767.00
Insider Selling (Last 12 Months): $234,728.97

Nautilus Biotechnology Insider Trading History Chart

This chart shows the insider buying and selling history at Nautilus Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$53kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Nautilus Biotechnology Share Price & Price History

Current Price: $0.89
Price Change: Price Decrease of -0.0493 (-5.26%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for NAUT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.89Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for Nautilus Biotechnology (NASDAQ:NAUT)

50.71% of Nautilus Biotechnology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NAUT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$697kbought$490ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal InflowsTotal Outflows
Nautilus Biotechnology logo
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More on Nautilus Biotechnology

Today's Range

Now: $0.89
Low: $0.88
High: $0.93

50 Day Range

MA: $1.44
Low: $0.89
High: $2.04

52 Week Range

Now: $0.89
Low: $0.88
High: $3.09

Volume

78,119 shs

Average Volume

98,920 shs

Market Capitalization

$111.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Who are the company insiders with the largest holdings of Nautilus Biotechnology?

Nautilus Biotechnology's top insider investors include:
  1. Sujal M Patel (CEO)
  2. Mary E Godwin (VP)
Learn More about top insider investors at Nautilus Biotechnology.

Who are the major institutional investors of Nautilus Biotechnology?

Nautilus Biotechnology's top institutional shareholders include:
  1. Bain Capital Life Sciences Investors LLC — 1.40%
  2. Geode Capital Management LLC — 0.91%
  3. Dimensional Fund Advisors LP — 0.61%
  4. ArchPoint Investors — 0.48%
  5. Northern Trust Corp — 0.38%
  6. Wexford Capital LP — 0.26%
Learn More about top institutional investors of Nautilus Biotechnology stock.

Which major investors are selling Nautilus Biotechnology stock?

During the last quarter, NAUT stock was sold by these institutional investors:
  1. Bain Capital Life Sciences Investors LLC
  2. Alyeska Investment Group L.P.
  3. Sentinel Trust Co. LBA
  4. Northern Trust Corp
  5. Charles Schwab Investment Management Inc.
  6. ArchPoint Investors

Which major investors are buying Nautilus Biotechnology stock?

During the previous quarter, NAUT stock was acquired by institutional investors including:
  1. Citadel Advisors LLC
  2. JPMorgan Chase & Co.
  3. Wexford Capital LP
  4. Renaissance Technologies LLC
  5. Dimensional Fund Advisors LP
  6. Jane Street Group LLC
  7. Millennium Management LLC
  8. Hsbc Holdings PLC